Atrial Fibrillation | Pharmacor | G7 | 2014
Last Updated 22 December 2014
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. AF is a major cause of morbidity and mortality and is therefore a substantial public health and finance burden; it is also increasing in prevalence across the pharmaceutical markets discussed in this report owing to population aging. The emergence of several new agents for stroke risk reduction in AF patients has satisfied a major unmet need; however, the need for safe and effective agents to restore normal sinus rhythm is increasing due to the aging population and the limitations of existing agents. Drugs in development have the potential to alter treatment patterns, reduce the burden of AF, and dramatically improve patient outcomes.
